Sermorelin is a synthetic peptide reproducing the first 29 amino acids of growth hormone-releasing hormone (GHRH), the shortest fragment of the natural hormone that still carries full biological activity. Rather than supplying growth hormone directly, it binds GHRH receptors on the anterior pituitary and prompts the gland to release its own growth hormone in the body's natural pulsatile pattern, so normal feedback controls stay intact. The regulatory reality frames every claim below: sermorelin is no longer an FDA-approved finished product, its current use in adults is almost entirely off-label through compounding pharmacies, and its long-term evidence base is thinner than that of established hormone therapies.
Sermorelin is a synthetic GHRH(1-29) analog that stimulates the pituitary to release its own growth hormone in a natural pulsatile pattern, and since the withdrawal of the FDA-approved product Geref it is used in adults almost entirely off-label through compounding pharmacies.
The published mechanism describes sermorelin as a 29-amino-acid copy of the active head of GHRH, and researchers found that this GRF(1-29) segment retains essentially all of the parent hormone's ability to trigger growth hormone release. Injected under the skin, it binds the GHRH receptor on pituitary somatotroph cells and activates the cyclic-AMP pathway that drives those cells to make and secrete growth hormone in discrete bursts. That pulsatile release is the reported distinction from recombinant human growth hormone, which floods the bloodstream with a steady dose of the finished hormone.
Because sermorelin acts one step upstream of growth hormone by stimulating an intact pituitary rather than supplying the finished hormone, the body's own somatostatin and IGF-1 feedback loops remain in control, making supraphysiologic growth hormone levels far less likely than with recombinant HGH.
The record separates a narrow approved history from a much broader off-label present. As the drug Geref, sermorelin's formally approved role was pediatric: treating idiopathic growth hormone deficiency in children, and, in a related formulation, serving as a diagnostic agent to test whether a child's pituitary could release growth hormone when stimulated. Since the branded product left the market, essentially all current use is off-label and centered on adults, where the most defensible rationale is adult growth hormone deficiency and the broadest use is a wellness and anti-aging market that outruns the published evidence.
Sermorelin's only formally FDA-approved indication was pediatric growth hormone deficiency under the withdrawn drug Geref, and every current use in adults, from documented adult GH deficiency to the far more common wellness and anti-aging market, is off-label.
Sermorelin does not currently exist as an FDA-approved finished drug product in the United States. It once did, as sermorelin acetate marketed under the name Geref, but that product was discontinued in the late 2000s for business reasons rather than a safety finding, and no replacement branded product followed. With no approved manufacturer, lawful access today runs almost entirely through compounding pharmacies filling a valid prescription, a supply that can shift with regulatory interpretation as the FDA scrutinizes whether certain peptides meet the statutory ingredient categories.
Sermorelin has no FDA-approved finished product in the United States, so lawful access runs almost entirely through 503A and 503B compounding pharmacies against a valid prescription, and while it is not a scheduled controlled substance, growth hormone secretagogues are prohibited in competitive sport by the World Anti-Doping Agency.
The published protocols describe sermorelin as a subcutaneous injection given with a fine insulin-style needle into the abdomen, thigh, or upper arm, with site rotation to limit local irritation. The near-universal instruction in these protocols is a bedtime dose, timed to reinforce the body's largest natural growth hormone pulse during early deep sleep. Because it is supplied as a lyophilized powder, protocols call for reconstitution with sterile diluent, refrigerated storage, and attention to expiration once mixed, since improper storage degrades the molecule.
Published sermorelin protocols describe a subcutaneous dose of a few hundred micrograms taken at night on a relatively empty stomach, with IGF-1 the primary monitoring marker used to keep the dose within a physiologic range.
The benefits attributed to sermorelin follow from what growth hormone and IGF-1 do, so clinics point to gradual gains in lean mass, reductions in fat, better recovery, stronger connective tissue, improved skin, and deeper sleep with knock-on effects on energy and mood. The important qualifier is that the strength of the evidence does not match the confidence of the claims: the best-supported data come from the original pediatric and diagnostic uses, while rigorous, long-term, placebo-controlled trials in healthy aging adults are limited. Much of what is cited is mechanistic reasoning, short studies, or clinic experience rather than large controlled trials.
The body-composition, sleep, and anti-aging benefits marketed for sermorelin rest largely on mechanistic reasoning and short studies rather than long-term placebo-controlled human trials, and the coherent physiologic rationale applies to diagnosed growth hormone deficiency far more than to healthy adults already within the normal range.
The literature describes sermorelin as generally well tolerated, with the most common adverse effects mild and local: pain, redness, swelling, or itching at the injection site that usually settles on its own and is reduced by rotating locations. The more serious concerns are theoretical rather than commonly observed, and they flow from the fact that sermorelin raises growth hormone and IGF-1, both growth signals. A frank limitation is that sermorelin lacks the large, long-duration safety datasets that established therapies carry, so the true frequency of rare or delayed harms in healthy adults is not well characterized.
Sermorelin's common side effects are mild and local, but its serious risks are largely theoretical extensions of raising IGF-1, so active malignancy is treated as a contraindication, and because supply runs through compounding and unregulated vendors, purity and sterility are not guaranteed and warrant medical attention for signs of a significant allergic reaction, persistent severe headache, or vision changes.
The clearest contrast in the record is with recombinant human growth hormone, which supplies the finished hormone directly, raises levels reliably and powerfully, and bypasses the body's regulation, making it easier to overshoot into supraphysiologic ranges and more tightly regulated and expensive. Sermorelin instead nudges the pituitary to release its own growth hormone within the natural feedback loop, which supporters describe as gentler and self-limiting but which cannot work if the pituitary itself is incapable of responding. Within the secretagogue family, sermorelin is a GHRH analog whose closest relative is the longer-acting CJC-1295, and it is often paired with a ghrelin-receptor peptide such as ipamorelin working through a separate pathway.
| Agent | Mechanism | Reported profile |
|---|---|---|
| Recombinant HGH | Supplies finished growth hormone directly | Powerful and reliable, bypasses feedback, tightly regulated and expensive |
| Sermorelin | GHRH analog, short half-life | Brief sharp pulse within natural feedback, gentler but weaker and less certain |
| CJC-1295 | Modified GHRH analog, resists breakdown | Longer-lasting, more sustained signal than sermorelin |
| Ipamorelin / GHRP-6 | Ghrelin-receptor secretagogues | Separate pathway, often paired with a GHRH analog for a synergistic pulse |
Sermorelin is positioned as a lower-intensity, lower-cost, more physiologic option than direct recombinant HGH, trading a weaker and less certain effect for feedback-limited release, and because the GHRH and ghrelin-receptor pathways are complementary, it is frequently paired with a GHRP such as ipamorelin for a larger combined pulse.
Because sermorelin is a compounded rather than a branded drug, there is no single list price; the monthly cost depends on dose, pharmacy, and whether it is bundled with other peptides, but it commonly lands in the range of roughly one hundred to a few hundred dollars per month for the medication itself. That figure is rarely the whole picture, since legitimate access requires a prescription and the clinical relationship behind it, including initial evaluation, baseline and follow-up bloodwork, and periodic consultations. Insurance almost never covers sermorelin prescribed off-label for wellness, so most patients pay out of pocket.
Sermorelin's medication cost commonly runs roughly one hundred to a few hundred dollars per month as a compounded drug, is rarely covered by insurance when prescribed off-label, and carries the added cost of the required prescriber relationship and monitoring bloodwork, while gray-market vials without a prescription forfeit any guarantee of identity, purity, or sterility.
The most defensible candidate in the record is an adult with signs and symptoms of low growth hormone activity, such as reduced lean mass, poor recovery, and low energy, supported by objective findings like a low IGF-1 level and, where warranted, formal testing of the axis, in whom an intact but underperforming pituitary can plausibly be coaxed to release more of its own hormone. Evaluation before starting typically includes medical history, symptom review, and baseline labs, with a careful prescriber screening for conditions that make treatment unwise. Because sermorelin depends on a pituitary that can still respond, it makes little sense where deficiency stems from structural pituitary damage.
The most defensible candidate for sermorelin is a symptomatic adult with a documented low IGF-1 and a responsive pituitary, while active malignancy, pregnancy, and breastfeeding are firm contraindications, and because the drug is prescribed off-label in a lightly regulated space, candidacy is a decision for a licensed prescriber who takes responsibility for monitoring rather than a self-assessment.
Educational use only. This article describes what the published scientific and clinical literature reports about Sermorelin. It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
Talk to a licensed prescriber. Whether a treatment described here is appropriate for you depends on your medical history, your current medications, and the monitoring you may need. A licensed healthcare provider can evaluate your situation.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
